<DOC>
	<DOCNO>NCT00337454</DOCNO>
	<brief_summary>This study compose Phase I Phase II part . Phase I part : The objective evaluate safety BMS-354825 subject chronic phase Chronic Myelogenous Leukemia ( CML ) . Dosage BMS-354825 50 mg BID , 70 mg BID 90 mg BID . Phase II part : The objective evaluate efficacy BMS-354825 . dosage decide accord result Phase I part . Treatment period 6 month subject chronic phase CML , 3 month subject accelerate phase blast phase CML Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia ( Ph+ALL )</brief_summary>
	<brief_title>Study BMS-354825 Subjects With CML Who Are Resistant Intolerant Imatinib Ph+All Japan</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Philadelphia chromosome positive bcrabl gene positive Chronic Myelogenous Leukemia ( CML ) Subjects must primary acquire resistance imatinib mesylate intolerance imatinib mesylate Philadelphia Chromosome Positive Acute Lymphoblastic leukemia ( Ph+ALL ) Subjects must primary acquire resistance chemotherapy intolerance chemotherapy Performance status ( general condition ) specify Eastern Cooperative Oncology Group : 02 Men woman , age 20 75 Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 3 month study manner risk pregnancy minimize Subjects eligible willing undergo transplantation prestudy Women pregnant breastfeeding Uncontrolled significant cardiovascular disease History significant bleeding disorder unrelated CML ALL Adequate hepatic function Adequate renal function Medication increase bleed risk Medication change heart rhythm Subjects compulsorily detain legal reason treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Imatinib resistant intolerant CML</keyword>
	<keyword>Treatment resistant intolerant Ph+ALL</keyword>
</DOC>